Abstract
The human genome project was initiated in 1990 to study the structure and characteristics of human DNA that are important for understanding gene functions and their relation to diseases. The large-scale genome research has driven the technology advancement in genetic testing, drug design, gene therapy, and other genetic related areas such as pharmacogenetics. Although the project reveals potential benefits, it raises ethical, legal, and social issues. The outcomes of individuals’ genetic information disclosure may lead to confidentiality and genetic discrimination issues. In addition, clinical relevance of genetic testing and psychological effect from the results are debatable. This article discusses the potential benefits and risks from the human genome project.
Similar content being viewed by others
References
Fink L, Collins FS. The human genome project: View from the National Institutes of Health. J Am Med Worn Assoc. 1997;52(1):4–7,15.
Cantor CR. A brief sketch of the Human Genome Project and its implications for pharmaceutical technology. Pharmaceut Tech. 1993;17:22,24,26.
The Human Genome Project. Revised 5-year research goals of the U.S. Human Genome Project. Human Genome News. 1993;5(4):1–5.
The Human Genome Project. Technology transfer—Commercializing genome resource. Human Genome News. 1995:7(3–4):15.
Kadlec JV, McPherson RA. Ethical issues in screening and testing for genetic diseases. Clin Lab Med. 1995;15(4):989–999.
Ellsworth DL, Hallman DM, Boerwinkle E. Impact of the Human Genome Project of epidemiologic research. Epidemiologic Rev. 1997;19(1):3–13.
Scriver CR. Genetic screening, testing and treatment: How far can we go? J Inher Metab Dis. 1996;19:401–411.
Olopade OI. The Human Genome Project and breast cancer. Women’s Health Issues. 1997;7(4):209–214.
Mansfield BK. The Genome Project and the Pharmaceutical Industry. Human Genome News. 1990;2(4):1.
Kelloff GJ, Hawk ET, Karp JE, Crowell JA, et al. Progress in clinical chemoprevention. Sem Oncology. 1997;24(2):241–252.
Kalow W. Pharmacogenetics: Its place in medicine and biology. J Pharmacy Practice. 1992;6:312–316.
Hildebrand CE, Stallings RL, Torney DC, Fickett JW, et al. Human genome mapping and sequencing: Applications in Pharmaceutical Science. In: Pezzuto JM, Johnson ME, Manzsse HR, Ed. Biotechnology and Pharmacy. New York: Chapman & Hall; 1993.
Tucker GT. Clinical implications of genetic polymorphism in drug metabolism. J Pharm Pharmacol. 1994;46(Suppl 1):417–424.
Meyer UA. The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol. 1994;46(Suppl 1):409–415.
Sandhu JS, Keating A, Hozumi N. Human gene therapy. Crit Rev Biotech. 1997;17(4):307–326.
Smith TJ. Gene therapy: Opportunities for pharmacy in the 21st century. Am J Pharmaceut Educ. 1996;60:213–215.
Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 4th ed. New York: Oxford University Press; 1994.
Kopala B. The Human Genome Project: Issues and ethics. Am J Maternal Child Nursing. 1997;22:9–12.
Blanck PD, Marti MW. Genetic discrimination and the employment provisions of the Americans with Disabilities Act: Emerging legal, empirical, and policy implications. Behavioral Sci Law. 1996;14:411–432.
Patenaude AF. The genetic testing of children for cancer susceptibility: Ethical, legal, and social issues. Behavioral Sci Law. 1996;14:393–410.
Wilfond BS, Noland K. National policy development for the clinical application of genetic diagnostic technologies. JAMA. 1993;270(24):2948–2954.
Cassel CK. Policy implications of the Human Genome Project for women. Women’s Health Issues. 1997;7(4):225–229.
Mahowald MB, Levinson D, Cassel C, Lemke A, et al. The new genetics and women. Milbank Quarterly. 1996;74(2):239–283.
Nsiah-Jefferson L. Reproductive genetic services for low-income women and women of color: Access and sociocultural issue. In: Rothenberg KH, Thomsom EJ, eds. Women and Prenatal Testing: Facing the Challenges of Genetic Technology. Columbus, OH: Ohio State University Press; 1994.
Ravine D, Cooper DN. Adult-onset genetic disease: mechanisms, analysis and prediction. Q J Med. 1997;90:83–103.
Salkovskis PM, Rimes KA. Predictive genetic testing: psychological factors. J Psychosomatic Res. 1997;43(5):477–487.
Scriver CR. We mean well: Treatment of Mendelian disease. Acta Paediatr Japonica. 1988;30:385–389.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wattanapitayakul, S., Schommer, J.C. The Human Genome Project: Benefits and Risks to Society. Ther Innov Regul Sci 33, 729–735 (1999). https://doi.org/10.1177/009286159903300310
Published:
Issue Date:
DOI: https://doi.org/10.1177/009286159903300310